Clinical medicine profile
Medroxyprogesterone
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC.
Precautions
- Obtain allergy and medication history.
- Adjust for renal/hepatic impairment, pregnancy, lactation, extremes of age and interacting drugs.
- Use the lowest effective dose for the shortest appropriate duration.
- Monitor for expected class adverse effects.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Dose: Tablets: Secondary amenorrhea: abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer:5-10mg daily from 16th-21st day of the cycle for 5-10 days. Endometriosis: 10mg TID from day one of the cycle for 90 days. Primary and secondary amenorrhoea: 5-10mg daily for 10 days. Menopause: 10mg-20mg daily continuously. Hormone replacement therapy with oestrogen: 5-10mg daily from 16th - 21st day of estrogen therapy. Sterile Aqueous Suspension: Adjunctive therapy and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma. Contraceptive Injection: Medroxyprogesterone acetate contraceptive injection is indicated only for the prevention of pregnancy. It is administered at 3-month [13-week] intervals.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as fibroids or uterine cancer, endometriosis primary and secondary amenorrhoea, menopause and hormone replacement therapy with oestrogen.
- 150mg injection used as progesterone-only contraceptive
Adverse effects
- Hypersensitivity reactions
- changes in libido
- GI disturbances
- weight gain
- breakthrough bleeding
- breast changes
- mental depression
- and fluid retention.
Drug interactions
Open multi-drug checker ↗- Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
- Document allergy status and key interactions.
Mechanism & disposition
A true progesterone-derivative Mechanism is agent-specific.
Read complete mechanism
A true progesterone-derivative Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.